This archive covers milestones and breakthroughs from the scientific and academic world — researchers, universities, and institutions whose work advances human knowledge. Stories here highlight discoveries, studies, and scholarly efforts that point toward a better future.
The researchers are now investigating whether they can release infected mosquitoes into the wild, or use spores to suppress the disease, in order to reduce the incidence of the disease among humans.
In a motion passed by Oxford’s governing body, the Congregation, which is made up of 5,500 academic and administrative members, the university is now required to cut all ties with fossil fuel firms and end future investment in these companies.
Scientists at Cornell University have engineered a new fishing net material that offers comparable strength to today’s solutions but can break down much more quickly when exposed to UV light.
The first patients have been enrolled in human trials for a coronavirus vaccine at the historic University of Oxford after the U.K.’s Health Secretary said the country would be “throwing everything” behind the project.
Results from the trial were “really, really encouraging”, the project’s lead scientist Daniel Harrison from Southern Cross University said.
Mental health conditions such as obsessive compulsive disorder (OCD) could be treated in a new way using drugs that target the immune system instead of the central nervous system, suggests exciting new research.
The new treatment is rapidly approaching human trials and hopes to have an FDA-approved treatment out the other end of the pipeline in 2-3 years.
While the six-junction III-V technology underlying these new cells is likely too costly at this time to be put to use in everyday rooftop applications, the new cell has great potential for application in concentrated solar panel arrays.
In several of the patients the virus cleared up entirely, leading the authors to conclude that plasma “can serve as a promising rescue option” for severe COVID-19 cases.
“There’s never been a therapy for treatment-resistant depression that’s broken 55% remission rates in open-label testing,” the team says.
